Ceftazidime + AvibactamThird Party Manufacturing in India

Ceftazidime + Avibactam works through a dual mechanism where ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, and avibactam protects it by reversibly inhibiting class A, class C, and some class D beta-lactamase enzymes. It maintains antibiotic integrity to help the body eradicate resistant Gram-negative bacteria. Unlike older beta-lactamase inhibitor combinations, it neutralizes extended-spectrum beta-lactamases and Klebsiella pneumoniae carbapenemases. It is highly effective and well-tolerated in treating critical hospital-acquired infections.

Therapeutic Uses

• Complicated Intra-abdominal Infections: Used alongside metronidazole to clear deep abdominal bacterial infections.
• Hospital-Acquired Bacterial Pneumonia: Resolves severe lower respiratory infections caused by resistant pathogens.
• Complicated Urinary Tract Infections: Eradicates advanced pyelonephritis cases showing high antibiotic resistance.

Why Manufacturers Choose Ceftazidime + Avibactam

This premium antibiotic combination is a primary choice for managing multi-drug resistant Gram-negative infections in modern hospitals. Selecting Ceftazidime + Avibactam third party manufacturing in India via Celesta places your brand at the forefront of the high-tier critical care marketplace. Our production facilities are WHO-GMP certified, maintaining strict climate controls and advanced sterile co-blending processes to ensure perfect active ratio uniformity across every dry injection batch.